American Journal of Cardiovascular Drugs

, Volume 14, Issue 3, pp 217–227 | Cite as

Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers

  • Tommy Andersson
  • Peter Nagy
  • Mohammad Niazi
  • Sven Nylander
  • Hal Galbraith
  • Santosh Ranjan
  • Lars Wallentin
Original Research Article



The effect of proton pump inhibitors (PPIs) on the pharmacokinetics and pharmacodynamics of clopidogrel was assessed in two healthy volunteer crossover studies.

Subjects and methods

Study 1: subjects received clopidogrel alone (300-mg loading dose, then 75 mg/day for 28 days) and two of three PPIs (omeprazole 80 mg, esomeprazole 40 mg or lansoprazole 60 mg) plus clopidogrel for 29 days in three treatment periods (randomized treatment sequence assignment). Study 2: subjects received clopidogrel alone (75 mg/day for 9 days) and clopidogrel alone for 4 days followed by clopidogrel plus fixed-combination esomeprazole 20 mg/low-dose acetylsalicylic acid (ASA) 81 mg for 5 days in two treatment periods (randomized treatment sequence assignment). Pharmacokinetic effects were estimated by measuring active metabolite of clopidogrel, and pharmacodynamic effects by inhibition of adenosine diphosphate (ADP)-induced platelet aggregation.


There was a relative decrease of up to 50 % in exposure to the active metabolite of clopidogrel with the different PPIs (study 1), and close to 40 % with esomeprazole/low-dose ASA (study 2), compared with clopidogrel alone. There was an absolute decrease of up to 17 % in inhibition of ADP-induced platelet aggregation with co-administration of different PPIs, compared with clopidogrel alone; however, no differences in platelet inhibition were observed during co-administration with the esomeprazole/low-dose ASA fixed-dose combination.


Omeprazole, esomeprazole and lansoprazole decreased systemic exposure to the active metabolite of clopidogrel in healthy volunteers, leading to modest decreases in its antiplatelet effect. However, no apparent differences in platelet inhibition were observed when esomeprazole was co-administered with low-dose ASA as a fixed-dose combination.



This study was supported by AstraZeneca R&D, Mölndal, Sweden. Medical writing support was provided by Lisa M. Klumpp Callan and Steve Winter of inScience Communications, Springer Healthcare and funded by AstraZeneca.

Conflicts of interest/Disclosure

T. Andersson, P. Nagy, M. Niazi and S. Nylander are employees of AstraZeneca. H. Galbraith and S. Ranjan are employees of Quintiles, who conducted the studies with funding from AstraZeneca. L. Wallentin has received research grants from AstraZeneca.

Author Contributions

Study conception, design and monitoring, and interpretation of data: T. Andersson, P. Nagy, M. Niazi, and S. Nylander.

Study design, conduct, analysis and interpretation of data: H. Galbraith and S. Ranjan.

Interpretation of data: L. Wallentin.

All authors contributed to drafting of the article and approved the final version to be published.


  1. 1.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–39.CrossRefGoogle Scholar
  2. 2.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. doi: 10.1056/NEJMoa010746.PubMedCrossRefGoogle Scholar
  3. 3.
    Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205–41. doi: 10.1016/j.jacc.2009.10.015.PubMedCrossRefGoogle Scholar
  4. 4.
    Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49. doi: 10.1038/ajg.2010.445.PubMedCrossRefGoogle Scholar
  5. 5.
    Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795–801. doi: 10.1111/j.1365-2036.2005.02649.x.PubMedCrossRefGoogle Scholar
  6. 6.
    Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69–75. doi: 10.1016/j.ijcard.2010.10.027.PubMedCrossRefGoogle Scholar
  7. 7.
    Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827–30.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16(11):1945–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8. doi: 10.1136/gut.2005.080754.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Nema H, Kato M, Katsurada T, Nozaki Y, Yotsukura A, Yoshida I, et al. Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease. J Clin Gastroenterol. 2009;43(2):130–2. doi: 10.1097/MCG.0b013e3181580e8a.PubMedCrossRefGoogle Scholar
  11. 11.
    Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89. doi: 10.1056/NEJMoa050522.PubMedCrossRefGoogle Scholar
  12. 12.
    Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–21. doi: 10.1016/S0140-6736(05)67660-X.PubMedCrossRefGoogle Scholar
  13. 13.
    Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78. doi: 10.1056/NEJMoa0901301.PubMedCrossRefGoogle Scholar
  14. 14.
    Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17. doi: 10.1056/NEJMoa060989.PubMedCrossRefGoogle Scholar
  15. 15.
    Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7. doi: 10.1016/S0140-6736(04)16721-4.PubMedCrossRefGoogle Scholar
  16. 16.
    Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475–84. doi: 10.1177/0091270008315310.PubMedCrossRefGoogle Scholar
  17. 17.
    Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65–74.PubMedCrossRefGoogle Scholar
  18. 18.
    Harmsze AM, van Werkum JW, Taubert D, Hackeng CM, Deneer VH. Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel’s active metabolite. Ann Pharmacother. 2011;45(4):542–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304–11. doi: 10.1016/j.jacc.2011.12.024.PubMedCrossRefGoogle Scholar
  20. 20.
    Wu J, Jia LT, Shao LM, Chen JM, Zhong DD, Xu S, et al. Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. Eur J Clin Pharmacol. 2012. doi: 10.1007/s00228-012-1329-z. (Epub ahead of print).
  21. 21.
    Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012;33(5):278–83. doi: 10.1002/bdd.1795.PubMedCrossRefGoogle Scholar
  22. 22.
    Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012;42(7):633–40. doi: 10.3109/00498254.2011.653655.PubMedCrossRefGoogle Scholar
  23. 23.
    Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos Biol Fate Chem. 2010;38(1):92–9. doi: 10.1124/dmd.109.029132.PubMedCrossRefGoogle Scholar
  24. 24.
    Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735–41. doi: 10.1038/sj.clpt.6100139.PubMedCrossRefGoogle Scholar
  25. 25.
    Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008;23(6):412–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors—where do we stand in 2012? World J Gastroenterol. 2012;18(18):2161–71. doi: 10.3748/wjg.v18.i18.2161.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, et al. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost. 2011;105(4):696–705. doi: 10.1160/TH10-09-0582.PubMedCrossRefGoogle Scholar
  28. 28.
    Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120(23):2322–9. doi: 10.1161/CIRCULATIONAHA.109.873497.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17. doi: 10.1056/NEJMoa1007964.PubMedCrossRefGoogle Scholar
  30. 30.
    Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624–41. doi: 10.1111/j.1538-7836.2010.04049.x.PubMedCrossRefGoogle Scholar
  31. 31.
    Harjai KJ, Shenoy C, Orshaw P, Usmani S, Boura J, Mehta RH. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. Circ Cardiovasc Interv. 2011;4(2):162–70. doi: 10.1161/CIRCINTERVENTIONS.110.958884.PubMedCrossRefGoogle Scholar
  32. 32.
    Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474–82. doi: 10.1161/CIRCULATIONAHA.110.965640.PubMedCrossRefGoogle Scholar
  33. 33.
    Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. 2012;345:e4388. doi: 10.1136/bmj.e4388.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Harrison RW, Mahaffey KW. Clopidogrel and PPI interaction: clinically relevant or not? Curr Cardiol Rep. 2012;14(1):49–58. doi: 10.1007/s11886-011-0233-y.PubMedCrossRefGoogle Scholar
  35. 35.
    Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2012;35(1):165–74. doi: 10.1111/j.1365-2036.2011.04890.x.PubMedCrossRefGoogle Scholar
  36. 36.
    Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, et al. Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. J Atheroscler Thromb. 2012;19(6):559–69.PubMedCrossRefGoogle Scholar
  37. 37.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol. 2010;56(5):532–9. doi: 10.1097/FJC.0b013e3181f68209.PubMedCrossRefGoogle Scholar
  38. 38.
    Tunggal P, Ng FH, Lam KF, Chan FK, Lau YK. Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J. 2011;162(5):870–4. doi: 10.1016/j.ahj.2011.08.007.PubMedCrossRefGoogle Scholar
  39. 39.
    Niazi M, Andersson T, Naucler E, Sundin M, Naesdal J. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. Int J Clin Pharmacol Ther. 2009;47(9):564–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Andersson T, Morrison D, Nagy P, Pisupati J, Schettler J, Warner TD. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Am J Cardiovasc Drugs. 2012;12(4):217–24. doi: 10.2165/11634280-000000000-00000.PubMedGoogle Scholar
  41. 41.
    Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost. 2010;104(3):571–81. doi: 10.1160/TH09-11-0803.PubMedCrossRefGoogle Scholar
  42. 42.
    Liang Y, Johnston M, Hirsh J, Pare G, Li C, Mehta S, et al. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. J Thromb Thrombolysis. 2012;34(4):429–36. doi: 10.1007/s11239-012-0762-2.PubMedCrossRefGoogle Scholar
  43. 43.
    Ferreiro JL, Ueno M, Tomasello SD, Capodanno D, Desai B, Dharmashankar K, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv. 2011;4(3):273–9. doi: 10.1161/CIRCINTERVENTIONS.110.960997.PubMedCrossRefGoogle Scholar
  44. 44.
    Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.03.085. (Epub ahead of print).
  45. 45.
    Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients of acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824–34. doi: 10.1111/j.1365-2125.2012.04250.x.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Jaspers Focks J, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review. Heart. 2012. doi: 10.1136/heartjnl-2012-302371. (Epub ahead of print).

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Tommy Andersson
    • 1
  • Peter Nagy
    • 2
  • Mohammad Niazi
    • 1
  • Sven Nylander
    • 1
  • Hal Galbraith
    • 3
  • Santosh Ranjan
    • 4
  • Lars Wallentin
    • 5
  1. 1.AstraZeneca R&DMölndalSweden
  2. 2.Global Medicines DepartmentAstraZeneca R&DMölndalSweden
  3. 3.Clinical Pharmacology, QuintilesKansasUSA
  4. 4.Biostatistics, QuintilesKansasUSA
  5. 5.Uppsala Clinical Research CentreUppsalaSweden

Personalised recommendations